BACKGROUND: In systemic sclerosis (SSc), joint involvement may reduce the functional capacity of the hands. Intravenous immunoglobulins have previously been shown to benefit patients with SSc. AIM: To verify the efficacy of intravenous immunoglobulins on joint involvement and function in SSc. PATIENTS AND METHODS: 7 women with SSc, 5 with limited and 2 with diffuse SSc, with a severe and refractory joint involvement were enrolled in the study. Methotrexate and cyclophosphamide pulse therapy did not ameliorate joint symptoms. Hence, intravenous immunoglobulins therapy was prescribed at a dosage of 2 g/kg body weight during 4 days/month for six consecutive courses. The presence of joint tenderness and swelling, and articular deformities (due to primary joint involvement and not due to skin and subcutaneous changes) were evaluated. Before and after 6 months of treatment, patients were subjected to (1) Ritchie Index (RI) evaluation of joint involvement; (2) Dreiser Algo-Functional Index (IAFD) evaluation of hand joint function; (3) pain visual analogue scale (VAS) to measure joint pain; (4) Health Assessment Questionnaire (HAQ) to evaluate the limitations in everyday living and physical disability; and (5) modified Rodnan Skin Score for skin involvement. RESULTS: After 6 months of intravenous immunoglobulins therapy, joint pain and tenderness, measured with the VAS, decreased significantly (p<0.03), and hand function (IAFD) improved significantly (p<0.02), together with the quality of life (HAQ; p<0.03). All patients significantly improved, except for one. The skin score after 6 months of intravenous immunoglobulins therapy was significantly reduced (p<0.003). CONCLUSION: This pilot study suggests that intravenous immunoglobulins may reduce joint pain and tenderness, with a significant recovery of joint function in patients with SSc with severe and refractory joint involvement. The cost of intravenous immunoglobulins might limit their use only to patients who failed disease-modifying antirheumatic drugs.
BACKGROUND: In systemic sclerosis (SSc), joint involvement may reduce the functional capacity of the hands. Intravenous immunoglobulins have previously been shown to benefit patients with SSc. AIM: To verify the efficacy of intravenous immunoglobulins on joint involvement and function in SSc. PATIENTS AND METHODS: 7 women with SSc, 5 with limited and 2 with diffuse SSc, with a severe and refractory joint involvement were enrolled in the study. Methotrexate and cyclophosphamide pulse therapy did not ameliorate joint symptoms. Hence, intravenous immunoglobulins therapy was prescribed at a dosage of 2 g/kg body weight during 4 days/month for six consecutive courses. The presence of joint tenderness and swelling, and articular deformities (due to primary joint involvement and not due to skin and subcutaneous changes) were evaluated. Before and after 6 months of treatment, patients were subjected to (1) Ritchie Index (RI) evaluation of joint involvement; (2) Dreiser Algo-Functional Index (IAFD) evaluation of hand joint function; (3) pain visual analogue scale (VAS) to measure joint pain; (4) Health Assessment Questionnaire (HAQ) to evaluate the limitations in everyday living and physical disability; and (5) modified Rodnan Skin Score for skin involvement. RESULTS: After 6 months of intravenous immunoglobulins therapy, joint pain and tenderness, measured with the VAS, decreased significantly (p<0.03), and hand function (IAFD) improved significantly (p<0.02), together with the quality of life (HAQ; p<0.03). All patients significantly improved, except for one. The skin score after 6 months of intravenous immunoglobulins therapy was significantly reduced (p<0.003). CONCLUSION: This pilot study suggests that intravenous immunoglobulins may reduce joint pain and tenderness, with a significant recovery of joint function in patients with SSc with severe and refractory joint involvement. The cost of intravenous immunoglobulins might limit their use only to patients who failed disease-modifying antirheumatic drugs.
Authors: Sergio Generini; Günter Steiner; Irene Miniati; Maria L Conforti; Serena Guiducci; Karl Skriner; Olga Kaloudi; Roberto Giacomelli; Josef Smolen; Marco Matucci-Cerinic Journal: Rheumatology (Oxford) Date: 2009-05-29 Impact factor: 7.580
Authors: Y Levy; Y Sherer; A Ahmed; P Langevitz; J George; F Fabbrizzi; J Terryberry; M Meissner; M Lorber; J B Peter; Y Shoenfeld Journal: Lupus Date: 1999 Impact factor: 2.911
Authors: C Muscat; A Bertotto; R Ercolani; O Bistoni; E Agea; M Cesarotti; G Fiorucci; F Spinozzi; R Gerli Journal: Ann Rheum Dis Date: 1995-05 Impact factor: 19.103
Authors: Zoltán Szekanecz; Magdolna Aleksza; Péter Antal-Szalmás; Pál Soltész; Katalin Veres; Sándor Szántó; Zoltán Szabó; Anikó Végvári; Szilvia Szamosi; Gabriella Lakos; Sándor Sipka; Gyula Szegedi; John Varga; Gabriella Szücs Journal: Clin Rheumatol Date: 2008-12-06 Impact factor: 2.980
Authors: Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin Journal: Clin Rev Allergy Immunol Date: 2009-06 Impact factor: 8.667
Authors: Corrie L Poelman; Laura K Hummers; Fredrick M Wigley; Cynthia Anderson; Francesco Boin; Ami A Shah Journal: J Rheumatol Date: 2014-11-29 Impact factor: 4.666
Authors: Christina G Katsiari; Theodora Simopoulou; Ioannis Alexiou; Lazaros I Sakkas Journal: Hum Vaccin Immunother Date: 2018-07-16 Impact factor: 3.452